| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| C153444-1g | 1g | In stock | $36.90 | |
| C153444-5g | 5g | In stock | $108.90 | |
| C153444-25g | 25g | In stock | $487.90 |
| Synonyms | ceftizoxime|68401-81-0|Ceftizoxima|Ceftizoximum|Cefizox|Ceftizoximum [INN-Latin]|Ceftizoxima [INN-Spanish]|FK-749|Ceftizoxime (INN)|syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid|SKF-88373|Epocelin|C43C467DPE|(6R,7R)-7- |
|---|---|
| Specifications & Purity | >98.0%(HPLC) |
| Shipped In | Normal |
| Grade | Moligand™ |
| Product Description | Product Description： Ceftizoxime is a bacterial inhibitor which acts by interfering with bacterial cell wall synthesis and inhibiting cross-linking of the peptidoglycan. |
| Pubchem Sid | 488195842 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488195842 |
| IUPAC Name | (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| INCHI | InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1 |
| InChi Key | NNULBSISHYWZJU-LLKWHZGFSA-N |
| Canonical SMILES | CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=CCS3)C(=O)O |
| Isomeric SMILES | CO/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O |
| RTECS | XI0367375 |
| PubChem CID | 6533629 |
| Molecular Weight | 383.4 |
| Reaxy-Rn | 5777502 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 A2331240 | Certificate of Analysis | Aug 19, 2022 | C153444 |
| K2224030 | Certificate of Analysis | Aug 19, 2022 | C153444 |
| K2224033 | Certificate of Analysis | Aug 19, 2022 | C153444 |
| K2224042 | Certificate of Analysis | Aug 19, 2022 | C153444 |
| K2224258 | Certificate of Analysis | Aug 19, 2022 | C153444 |
| K2224259 | Certificate of Analysis | Aug 19, 2022 | C153444 |
| A2331182 | Certificate of Analysis | Nov 15, 2021 | C153444 |
| Specific Rotation[α] | 139° (C=1,0.1mol/L NaOH 3mL+H2O 7mL) |
|---|---|
| Melt Point(°C) | 227°C |
| Pictogram(s) | GHS08, GHS07 |
|---|---|
| Signal | Danger |
| Hazard Statements | H317:May cause an allergic skin reaction H334:May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P501:Dispose of contents/container to ... P284:[In case of inadequate ventilation] Wear respiratory protection. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P272:Contaminated work clothing should not be allowed out of the workplace. P333+P313:IF SKIN irritation or rash occurs: Get medical advice/attention. P362+P364:Take off contaminated clothing and wash it before reuse. P342+P316:If experiencing respiratory symptoms: Get emergence medical help immediately. |
| RTECS | XI0367375 |
| Reaxy-Rn | 5777502 |
| Merck Index | 1951 |
Starting at $38.90
Starting at $69.90
Starting at $100.90
| 1. Cui L, Neoh HM, Shoji M, Hiramatsu K. (2009) Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.. Antimicrob Agents Chemother, 53 (3): (1231-4). [PMID:19124662] |
| 2. Blaszczak LC, Brown RF, Cook GK, Hornback WJ, Hoying RC, Indelicato JM, Jordan CL, Katner AS, Kinnick MD, McDonald 3rd JH et al.. (1990) Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.. J Med Chem, 33 (6): (1656-62). [PMID:2342058] |
